WuXi PharmaTech Appoints Dr. Hui Cai as Vice President of Business Development

Thu. October 22, 2009; Posted: 05:43 AM

SHANGHAI, Oct 22, 2009 /PRNewswire-Asia via COMTEX/ -- WX | Quote | Chart | News | PowerRating -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced that Dr. Hui Cai has been appointed as Vice President of Business Development. She will report directly to Dr. Richard M. Soll, Senior Vice President of Integrated Services.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Prior to joining WuXi, Dr. Hui Cai was President of Inflexion BioPartners and Vice President of Corporate Development at HUYA Bioscience. Previously, Dr. Cai spent ten years at Johnson & Johnson Pharmaceutical Research and Development on multiple small molecule drug discovery programs, and is co- author and co-inventor to over 40 scientific publications and issued or pending patents. Dr. Cai was appointed by the Mayor of San Diego in 2002 as a Commissioner at City of San Diego Science and Technology Commission. She is Chair of the San Diego section of the American Chemical Society, and Chair of Board at SABPA (Sino-American Biomedical and Pharmaceutical Professionals Association). Dr. Cai received her B.S. and M.S. in Chemistry from Peking University, Ph.D. from The Scripps Research Institute, and M.B.A. from UCSD Rady School of Management as a recipient of the distinguished DLA Piper - Athena FlexMBA Scholarship.

"I am very pleased to welcome Hui on board as we continue to enhance our business development," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "Hui brings us a broad portfolio of expertise and experience in strategic planning, business development, and portfolio management, with which we are confident that our discovery business will grow rapidly."

SOURCE WuXi PharmaTech (Cayman) Inc.

http://www.wuxiapptec.com

For full details on Wuxi Pharmatech Cayman Inc (WX) click here. Wuxi Pharmatech Cayman Inc (WX) has Short Term PowerRatings of 4. Details on Wuxi Pharmatech Cayman Inc (WX) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

Tax Relief Bank Levy Wage Garnishment

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.